RHÖN-KLINIKUM AG | 02/26/2016

RHÖN-KLINIKUM AG: Provisional Figures for Financial Year 2015

  • 765,109 patients treated
  • Financial figures affected by special influences
  • Revenues amount to Euro 1.11 billion
  • EBITDA stands at Euro 154.2 million
  • Net consolidated profit amounts to Euro 87.4 million
  • Outlook for 2016: revenues between Euro 1.17 billion and Euro 1.20 billion, EBITDA between Euro 155 million and Euro 165 million


Bad Neustadt, 26th February 2016 

The sale of a total of 43 hospitals which was completed in 2014 again affected RHÖN‑KLINIKUM AG’s figures in the past financial year, albeit to a considerably lesser extent. Positive and negative one-off effects continued to influence the corporate results during the entire financial year 2015, their size was a low two-digit million figure and they partially cancelled each other out.

A total of 765,109 patients were treated at the five medical sites of our corporate group. Corporate revenues stood at Euro 1.11 billion with earnings before interest, taxes, depreciation and amortisation (EBITDA) amounting to Euro 154.2 million and net consolidated profit was at Euro 87.4 million.

“2015 was our first full financial year after the strategic re-orientation. Particular focus was placed on further medical innovations and improving nursing care. Our strategy continues to offer very good prospects for growth. With our unique campus concept the company is well-equipped for the future – particularly with respect to improving and modernising in‑patient/out-patient healthcare in rural areas,” said Dr. Martin Siebert, CEO of RHÖN-KLINIKUM AG.

“Following the second share repurchase scheme in 2015 we now have a very robust and solid financial basis for our future development,” said CFO Jens-Peter Neumann. “We are financially strong enough to achieve operative growth, to make investments in medical innovations and to take advantage of any acquisition opportunities – should they be suitable. Particularly in unsettling times our company continues to be an attractive investment opportunity in the capital market.”


The company expects revenues of Euro 1.17 billion to Euro 1.20 billion and earnings before interest, taxes, depreciation and amortisation (EBITDA) of between Euro 155 million and Euro 165 million for the current financial year 2016. Positive and negative one-off effects will continue to influence the corporate results during the current financial year as well, their size is a low to medium two-digit million figure and they will partially cancel each other out. They generally stem from handling the transaction with Fresenius/Helios, the first consolidation and integration of the municipal hospital in Bad Neustadt, special budgets for innovation and e-health, outstanding accounting issues and setting up a larger out-patient centre at the university hospital in Marburg.

Provisional, uncertified financial figures with possible rounding-off differences